Showing 1427 results
-
Press release /Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]…
-
Story /In Australia, a country where skin cancer rates remain high, cancer survivor Malcolm Caddies is on a mission to prevent the risks of sun exposure.
-
Story /For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.
-
Story /Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare…
-
Press release /Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with…
-
Press release /The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of…
-
Press release /Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
-
Press release /At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North…